University of Nebraska Medical Center

Sarah Lonowski, MD, MBA

Assistant Professor, UNMC Department of Dermatology
Director, Psoriasis-Psoriatic Arthritis Clinic, Nebraska Medicine
Co-Director, Multidisciplinary Autoimmune Skin Disease/Derm-Rheum Program, Nebraska Medicine

Sarah Lonowski, MD, MBA

Sarah Lonowski, MD, MBA, joined the UNMC Dermatology team as Co-Director of the Multidisciplinary Autoimmune Skin Disease/Derm-Rheum Program and Director of the Psoriasis-Psoriatic Arthritis clinic. Dr. Lonowski completed her dermatology residency at the University of California, Los Angeles (UCLA), where she served as Chief Resident in her final year. She then completed a highly specialized dermatology-rheumatology fellowship at Brigham and Women's Hospital, Harvard Medical school. She is board-certified in Dermatology.

A Colorado native, Dr. Lonowski completed her undergraduate degree and Master's in Business Administration at the University of Denver. She attended medical school at UCLA, where she was a member of the Alpha Omega Alpha Honor Society and was awarded the American Medical Women's Association Certificate of Commendation. She completed her internship in internal medicine at Cedars Sinai Hospital in Los Angeles.

Dr. Lonowski is passionate about dermatology-rheumatology/autoimmune connective tissue disease and other skin autoimmune diseases. She looks forward to training the next generation of dermatologists through teaching and clinical research. Outside of dermatology, Dr. Lonowski spends much of her time with her family, including her husband and young daughter. She enjoys traveling, reading, singing, and staying active outdoors.


  • Medical School: David Geffen School of Medicine, UCLA, 2013-2017
  • Internship: Cedars Sinai Medical Center, 2017-2018
  • Dermatology Residency: UCLA Division of Dermatology, Department of Medicine, 2018-2021
  • Rheumatology Fellowship: Brigham and Women’s Hospital, Harvard Medical School, 2021-2022
Key Publications
  • Lonowski S, Sachsman S, Patel N, Truong A, Holland V. Increasing evidence for omalizumab in the treatment of bullous pemphigoid. JAAD Case Rep. 2020 Feb 26;6(3):228-233. doi: 10.1016/j.jdcr.2020.01.002. PMID: 32140524; PMCID: PMC7044652.
  • Lonowski SL, Rodriguez O, Carlos CA, Forrestel AK, Kovarik CL, Wanat KA, Williams VL. Looking back on 10 years of the American Academy of Dermatology's Resident International Grant experience in Botswana. J Am Acad Dermatol. 2021 Sep;85(3):758-761. doi: 10.1016/j.jaad.2019.12.035. Epub 2019 Dec 20. PMID: 31866267.
  • Lonowski S, Goldman N, Kassamali B, Shahriari N, LaChance A, Vleugels RA. Tocilizumab for refractory morphea in adults: A case series. JAAD Case Rep. 2022 Oct 4;30:27-29. doi: 10.1016/j.jdcr.2022.09.024. PMID: 36353292; PMCID: PMC9637845.
  • Barry KK, Reusch DB, Shahriari N, Lonowski S, Dedeoglu F, Vleugels RA. Botulinum toxin for refractory Raynaud's phenomenon: A "how to" guide for pediatric patients. Pediatr Dermatol. 2023 Feb 25. doi: 10.1111/pde.15229. Epub ahead of print. PMID: 36840449.
  • Rotrosen ET, Zahedi Niaki O, Kassamali B, Lonowski S, Shahriari N, LaChance A, Vleugels RA. Intravenous Immunoglobulin and Dermatomyositis-Associated Venous Thromboembolism. JAMA Dermatol. 2023 May 10:e231105. doi: 10.1001/jamadermatol.2023.1105. PMID: 37163260; PMCID: PMC10173093.

Get to know Dr. Sarah Lonowski